Press release
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"text","content":"\nDr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company’s vaccine franchise\n\n SAN DIEGO--(BUSINESS WIRE)--\nArcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Markels will provide strategic oversight to the Company’s vaccine franchise and manufacturing processes.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213005428/en/John Markels, Ph.D. (Photo: Business Wire)\n“We are very pleased to welcome Dr. John Markels to the Arcturus Board,” said Joseph Payne, President & CEO of Arcturus. “John is an accomplished industry leader with exceptional vaccine and manufacturing expertise gained from a prolific career with Merck. John’s experience will be particularly valuable as we advance our pipeline of mRNA therapeutics and work alongside our strategic collaborator, CSL Seqirus, to develop and commercialize novel self-amplifying mRNA vaccines.”\n\n“Arcturus has pioneered a differentiated mRNA technology platform that is well positioned to lead a new class of highly effective vaccines for pathogens of global concern, as well as innovative medicines for certain important diseases. I look forward to working closely with the team to support the manufacturing and delivery of next generation mRNA medicines and vaccines globally,” said John Markels, Ph.D., Director at Arcturus.\n\nDr. Markels Biography\n\nDr. Markels has over 35 years of leadership experience in the pharmaceutical industry at Merck & Co., Inc., with a deep background in manufacturing, development, and technology transfer as well as global commercial, policy, and organizational development. Dr. Markels serves on the Board of Sangamo Therapeutics and chairs and serves on the advisory boards for the University of California, Berkeley College of Chemistry and University of Delaware Department of Chemi...